ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...118119120121122123124125126127128129130»
  • ||||||||||  Clinical, Journal:  A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment. (Pubmed Central) -  May 20, 2020   
    We have explicitly highlighted several useful information and facts like: i) No established relationship between progression of SARS-CoV-2 with temperature, humidity and/or both, ii) The underlying mechanism of SARS-CoV-2 is not fully understood, iii) Respiratory droplet size determines drop and airborne-based transmission, iv) Prognosis of COVID-19 can be done by its effects on various body organs, v) Infection can be stopped by restricting the binding of S protein and AE2, vi) Hydroxychloroquine is believed to be better than chloroquine for COVID-19, vii) Ivermectin with Vero-hSLAM cells is able to reduce infection by ~5000 time within 2 days, and viii) Nafamostat mesylate can inhibit SARS-CoV-2 S protein-initiated membrane fusion. We have also suggested future research perspectives, challenges and scope.
  • ||||||||||  ivermectin / Generic mfg.
    Ivermectin. 🙄 (Twitter) -  May 17, 2020   
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Declining soil transmitted helminth detections in an Australian tropical region. (Pubmed Central) -  May 17, 2020   
    Ivermectin is not recognised as having anti-cestode activity, hence the continued presence of H. nana endemically in the NT, suggests declines in STHs are not related to other changes in health hardware or existing mass drug administration programs. The reduction in T. trichiura detections may not be explained by this association, as unlike Strongyloides spp., the anti-helminthic effect of ivermectin has been less marked.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Rapid Progress toward Elimination of Strongyloidiasis in North Queensland, Tropical Australia, 2000-2018. (Pubmed Central) -  May 17, 2020   
    The seroprevalence of strongyloidiasis has declined markedly in this region of tropical Australia despite there being no targeted campaign to address the disease. Expanded prescription of ivermectin and public health interventions targeting the few remaining high-prevalence communities would be expected to expedite disease elimination.
  • ||||||||||  ivermectin / Generic mfg.
    Clinical, Journal:  Ivermectin dosing strategy to achieve equivalent exposure coverage in children and adults. (Pubmed Central) -  May 13, 2020   
    Median (90% confidence interval) clearance of 0.346 (0.12-0.73) L/h/kg in pre-school-aged (2-5 years) children is similar to 0.352 (0.17-0.69) L/h/kg in school-aged (6-12 years) children, but higher than in adults (0.199 (0.10-0.31) L/h/kg), resulting in significantly lower exposure in children following a 200 μg/kg dose. Simulations indicate that a dose increase to 300 and 250 μg/kg in children aged 2-5 and 6-12 years respectively, will achieve equivalent ivermectin exposure coverage in children and adults.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Strongyloides, HTLV-1 and small bowel obstruction. (Pubmed Central) -  May 13, 2020   
    He was diagnosed with Strongyloides hyperinfection with underlying human T-cell lymphotropic virus type 1 and treated with a prolonged course of ivermectin with ongoing monitoring for relapse. This case demonstrates a rare but potentially fatal cause of small bowel obstruction.